Representative Bruce Westerman (R-Arkansas) recently bought shares of Roche Holding AG (OTCMKTS:RHHBY). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Roche stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.
Representative Bruce Westerman also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
- Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
- Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
- Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
- Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
- Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
- Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
- Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
- Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
- Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.
Roche Trading Up 0.8 %
Roche stock opened at $38.90 on Friday. Roche Holding AG has a fifty-two week low of $29.20 and a fifty-two week high of $44.31. The firm has a 50 day moving average price of $40.92 and a 200 day moving average price of $38.55. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.
Institutional Investors Weigh In On Roche
Analysts Set New Price Targets
A number of research analysts recently issued reports on RHHBY shares. Morgan Stanley initiated coverage on Roche in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.
View Our Latest Research Report on RHHBY
About Representative Westerman
Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.
Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.
Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Articles
- Five stocks we like better than Roche
- What is the S&P/TSX Index?
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- What Are the U.K. Market Holidays? How to Invest and Trade
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- What Investors Need to Know About Upcoming IPOs
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.